Date="07/27/95" Citation="60 FR 38576" Group="legal" Type="NOTICE" Department="DEPARTMENT OF JUSTICE" Agency="DRUG ENFORCEMENT ADMINISTRATION (DEA), JUSTICE" Subject="Controlled Substances: Proposed Aggregate Production Quotas for 1996"

------------------------------------------------------------ Drug Enforcement Administration [DEA #134P] Controlled Substances: Proposed Aggregate Production Quotas for 1996 AGENCY: Drug Enforcement Administration (DEA), Justice. ACTION: Notice of proposed aggregate production quotas for 1996.

------------------------------------------------------------ Drug Enforcement Administration [DEA #134P] Controlled Substances: Proposed Aggregate Production Quotas for 1996 AGENCY: Drug Enforcement Administration (DEA), Justice. ACTION: Notice of proposed aggregate production quotas for 1996. + ------------------------------------------------------------ SUMMARY: This notice proposes initial 1996 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act. DATES: Comments or objections should be received on or before August 28, 1995. ADDRESSES: Send comments or objections to the Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn: DEA Federal Register Representative (CCR). FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 307-7183. SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator pursuant to sec 0.104 of Title 28 of the Code of Federal Regulations. The quotas are to provide adequate supplies of each substance for: (1) The estimated medical, scientific, research, and industrial needs of the United States; (2) lawful export requirements; and (3) the establishment and maintenance of reserve stocks. In determining the below listed proposed 1996 aggregate production quotas, the Deputy Administrator considered the following factors: (1) Total actual 1994 and estimated 1995 and 1996 net disposals of each substance by all manufacturers; (2) estimates of 1995 year-end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; and (3) projected demand as indicated by procurement quota applications filed pursuant to sec 1303.12 of title 21 of the Code of Federal Regulations. Pursuant to sec 1303.23(c) of title 21 of the Code of Federal Regulations, the Deputy Administrator of the DEA will, in early 1996, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 1995 year-end inventory and actual 1995 disposition data supplied by quota recipients for each basic class of Schedule I or II controlled substance. Therefore, under the authority vested in the Attorney General by section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by sec 0.100 of title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to sec 0.104 of title 28 of the Code of Federal Regulations, the Deputy Administrator hereby proposes that the aggregate production quotas for 1996 for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows: --------------------------------------------------------------+--------------- Basic class | Proposed | 1996 quotas --------------------------------------------------------------+--------------- | Schedule I: | Acetylmethadol.............................................. | 7 Alphacetylmethadol.......................................... | 7 Aminorex.................................................... | 7 Cathinone................................................... | 9 Difenoxin................................................... | 14,000 Dihydromorphine............................................. | 7 2,5-Dimethoxyamphetamine.................................... | 10,650,000 Dimethylamphetamine......................................... | 7 Ethylamine Analog of Phencyclidine.......................... | 5 N-Ethylamphetamine.......................................... | 7 Lysergic acid diethylamide.................................. | 58 Mescaline................................................... | 7 Methaqualone................................................ | 17 Methcathinone............................................... | 9 4-Methoxyamphetamine........................................ | 17 4-Methylaminorex............................................ | 2 3,4-Methylenedioxyamphetamine............................... | 17 3,4-Methylenedioxy-N-ethylamphetamine....................... | 27 3,4-Methylenedioxymethamphetamine........................... | 42 3-Methylfentanyl............................................ | 14 ---- page 38577 ---- Normethadone................................................ | 7 Normorphine................................................. | 7 Psilocybin.................................................. | 2 Psilocyn.................................................... | 2 Tetrahydrocannibinols....................................... | 55,100 Schedule II: | Alfentanil.................................................. | 8,500 Amobarbital................................................. | 15 Amphetamine................................................. | 1,300,100 Cocaine..................................................... | 550,040 Codeine (for sale).......................................... | 58,395,000 Codeine (for conversion).................................... | 16,632,000 Desoxyephedrine, 1,000,000 grams of levodesoxyephedrine for | 1,044,000 use in a noncontrolled, nonprescription product and 44 kg | for methamphetamine. | Dextropropoxyphene.......................................... | 118,066,000 Dihydrocodeine.............................................. | 60,000 Diphenoxylate............................................... | 1,063,000 Ecgonine (for conversion)................................... | 650,100 Ethylmorphine............................................... | 12 Fentanyl.................................................... | 120,100 Hydrocodone (for sale)...................................... | 8,880,000 Hydrocodone (for conversion)................................ | 2,800,000 Hydromorphone............................................... | 448,000 Isomethadone................................................ | 12 Levo-alpha-acetylmethadol................................... | 200,000 Levorphanol................................................. | 14,300 Meperidine.................................................. | 10,822,000 Methadone................................................... | 4,551,000 Methadone (for conversion).................................. | 364,000 Methadone Intermediate (for conversion)..................... | 5,534,000 Methamphetamine (for conversion)............................ | 723,000 Methylphenidate............................................. | 10,291,000 Morphine (for sale)......................................... | 12,450,000 Morphine (for conversion)................................... | 76,735,000 Noroxymorphone (for sale)................................... | 2,000 Noroxymorphone (for conversion)............................. | 2,406,000 Opium....................................................... | 1,226,000 Oxycodone (for sale)........................................ | 5,571,000 Oxycodone (for conversion).................................. | 37,300 Oxymorphone................................................. | 11,200 Pentobarbital............................................... | 15,100,000 Phencyclidine............................................... | 40 Phenylacetone (for conversion).............................. | 5,280,000 1-Phenylcyclohexylamine..................................... | 10 1-Piperidinocyclohexanecarbonitrile......................... | 12 Secobarbital................................................ | 400,000 Sufentanil.................................................. | 1,000 Thebaine.................................................... | 9,217,000 --------------------------------------------------------------+--------------- The Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in secsec 1308.11 and 1308.12 of title 21 of the Code of Federal Regulations be established at zero. All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief. In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing. The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment. The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq. The establishment of annual aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis. Dated: July 19, 1995. Stephen H. Greene, Deputy Administrator. [FR Doc. 95-18407 Filed 7-26-95; 8:45 am] BILLING CODE 4410-09-M ------------------------------------------------------ The Contents entry for this article reads as follows: Schedules of controlled substances; production quotas: Schedules I and II- 1996 proposed aggregate, 38576